Open Access Open Access  Restricted Access Subscription or Fee Access

Assessment of outcomes following high-dose opioid tapering in a Veterans Healthcare System

Lauren Hundley, PharmD, BCPS, Shelley Spradley, PharmD, BCPS, Scott Donelenko, BPharm, CPE

Abstract


Objective: To assess the impact of tapering of chronic high dose opioid therapy in veterans prompted by the implementation of the Opioid Safety Initiative in 2013.

Design: IRB and VA Office of Research and Development-approved retrospective, observational chart review.

Setting: North Florida/South Georgia Veterans Health System Patients: Veterans on high dose opioid therapy (300 mg of morphine equivalents per day) for chronic non-cancer pain as of 1/1/2012 with an opioid agreement discontinuation note documented in the medical record were included. Veterans treated for cancer pain or under palliative care were excluded.

Outcomes: Descriptive outcomes include rate of opioid discontinuation, average duration of tapering, and rate of relapse. Differences before and after discontinuation assessed include healthcare utilization, monitoring via urine drug screens and state prescription drug monitoring program (PDMP) queries, non-opioid analgesics, benzodiazepines, and non-pharmacologic modalities.

Results: Forty-three patients were included. The mean duration of therapy was 7.8 years and 81.4 percent were on methadone prior to tapering. Opioids were tapered to discontinuation in 28 patients (65 percent) with long-term abstinence in 71 percent. The mean duration of tapering was 81 days and the median/mode was 30 days. Statistically significant differences after tapering include decreased PDMP queries, increased non-opioid analgesics, decreased benzodiazepine prescriptions, and increased use of mental health services (p < 0.05). There were zero adverse outcomes identified in those tapered and one death in the group who sought non-VA care for continuation.

Conclusions: This study suggests that moderate speed tapering in high-risk veterans on chronic high-dose opioid therapy can be achieved, but caution is warranted in ensuring adequate follow-up and monitoring. Clinical pharmacy services may improve tapering outcomes by providing more frequent follow-up, monitoring via state PDMP queries to identify patients who have relapsed, and dispensing naloxone for increased safety.


Keywords


opioids, opioid analgesics, chronic pain, patient outcome assessment, outcome assessment, harm reduction

Full Text:

PDF

References


Dunn KM, Saunders KW, Rutter CM, et al.: Overdose and prescribed opioids: Associations among chronic non-cancer pain patients. Ann Intern Med. 2010; 152: 85-92.

Braden JB, Russo J, Fan MY, et al.: Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med. 2010; 170: 1425-1432.

Bohnert AS, Valenstein M, Bair MJ, et al.: Association between opioid prescribing patterns and opioid over dose related deaths. JAMA. 2011; 305: 1315-1321.

Rome JD, Townsend CO, Bruce BK, et al.: Chronic noncancer pain rehabilitation with opioid withdrawal: Comparison of treatment outcomes based on opioid use status at admission. Mayo Clin Proceed. 2004; 79: 759-768.

Baron MJ, McDonald PW: Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag. 2006; 2: 277-282.

Miller NS, Swiney T, Barkin RL: Effects of opioid prescription medication dependence and detoxification on pain perceptions and self-reports. Am J Ther. 2006; 13: 436-444.

Crisostomo RA, Schmidt JE, Hooten WM, et al.: Withdrawal of analgesic medication for chronic low-back pain patients: Improvement in outcomes of multidisciplinary rehabilitation regardless of surgical history. Am J Phys Med Rehabil. 2008; 87: 527.

Franklin GM, Mai T, Turner JA, et al.: Bending the prescription opioid dosing and mortality curves: Impact of the Washington State Opioid Dosing Guideline 2012. Am J Ind Med. 2015; 55: 325-331.

Dowell D, Haegerich TM, Chou R: CDC Guideline for prescribing Opioids for Chronic Pain—United States, 2016. JAMA. 2016; 315(15): 1624-1645.

The Opioid Therapy for Chronic Pain Work Group: VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. Version 3.0. 2017; Washington (DC): Veterans Health Administration and Department of Defense.

Anson P: Pain News Network. Survey: Opioid reduced or stopped for most patients. August 4, 2016. Available at https://www.painnewsnetwork.org/stories/2016/8/4/survey-opioidsstopped-or-reduced-for-most-patients. Accessed January 22, 2017.

Pain News Network. CDC survey results. Available at https://www.painnewsnetwork.org/cdc-survey-results/?rq=CDC%20Guidelines. Accessed January 22, 2017.

Scherrer J, Salas J, Copeland LA, et al.: Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. Ann Fam Med. 2016; 14: 54-62.

Kalra R, et al.: PAINWeek 2013. Abstract 45. Presented September 5, 2013. Described in: Proposed Opioid Reduction Guideline Reduces Depression, Pain. Medscape. 2013 Sept 13. Available at http://www.medscape.com/viewarticle/810954. Accessed May 8, 2017.

Ashrafioun L, Bishop TM, Conner KR, et al.: Frequency of prescription opioid misuse and suicidal ideation, planning, and attempts. J Psychiatr Res. 2017; 92: 1-7.

Frank JW: Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: A systematic review. [PowerPoint slides]. Presented on May 2, 2017 on VA Health Services Research & Development (HSR&D) Cyberseminar.

Frank J, Becker W, Krebs E, et al.: Systematic review of patient outcomes in dose reduction or discontinuation of chronic opioid therapy. PROSPERO 2015; CRD42015020347. Available at http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015020347. Accessed May 8, 2017.

Martell BA, O'Conner PG, Kerns RD, et al.: Systematic review: Opioid treatment for chronic back pain: Prevalence, efficacy, and association with addiction. Ann Intern Med. 2007; 146(2): 116-117.

Von Korff MR: Long-term use of opioid for complex chronic pain. Best Pract Res Clin Rheumatol. 2013; 27: 663-672.

Lin LA, Bohnert AS, Kerns RD, et al.: Impact of the opioid safety initiative on opioid-related prescribing in veterans. Pain. 2017; 158(5): 833-839.

Morasco BJ, Krebs EE, Cavanagh R, et al.: Treatment changes following aberrant urine drug test results for patients prescribed chronic opioid therapy. J Opioid Manag. 2015; 11(1): 45-51.

Lovejoy TI, Morasco BJ, Dernidenko MI, et al.: Reasons for discontinuation of long-term opioid therapy in patients with and without substance use disorders. Pain. 2017; 158(3): 526-534.

Kertesz SG: Opioids, Addiction, and Pain: Briefing for policy leaders. 2017 Feb 18. Available at https://edsinfo.wordpress.com/2017/02/20/opioids-addiction-and-pain-briefing-for-policy-leaders/. Accessed May 20, 2017.

Weeks WB: Hailey. JAMA. 2016; 316(19): 1975-1976.

Berna C, Kulich RJ, Rathmel JP: Tapering long-term opioid therapy in chronic non-cancer pain: Evidence and recommendations for everyday practice. May Clin Prog. 2015; 90(6): 828-842.

Jamison RN, Ross EL, Michna E, et al.: Substance misuse treatment for high-risk chronic pain patients on opioid therapy: A randomized trial. Pain. 2010; 150(3): 390-400.

Management of Acute Drug Withdrawal: Opiate withdrawal. In Perry PJ, Alexander B, Liskow BI, and DeVane CL (eds.): Psychotropic Drug Handbook, 8th edition. Baltimore, MD: Lippincott Williams & Wilkins, 2007, 454-490.

Center for Substance Abuse Treatment. Protracted Withdrawal. Substance Abuse Treatment Advisory. 2010. U.S. Department of Health and Human Services Publication No. (SMA) 10-4554. Available at http://store.samhsa.gov/shin/content/SMA10-4554/SMA10-4554.pdf. Accessed May 16, 2017.

Pain Management Opioid Taper Decision Tool. Washington, DC: Pharmacy Benefits Management Services, Academic Detailing Service, Veterans Health Administration, Department of Veterans Affairs; October 2016. Available at https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf. Accessed May 16, 2017.

Mudra SA: Pain Management Processes at North Florida/South Georgia Health Care System. 2016. Available at https://www.vapulse.net/community/care-topics/pain-management. Accessed May 16, 2017.

Gudin JA, Laitman A, Nalamachu S: Opioid related endocrinopathy. Pain Med. 2015; 16(suppl 1): S9-S15. Accessed May 16, 2017.

Ali K, Raphael J, Khan S, et al.: The effects of opioids on the endocrine system: An overview. Postgrad Med J. 2016; 92(1093): 677-681.

Deyo RA, Smith DH, Johnson ES, et al.: Prescription opioids for back pain and use of medications for erectile dysfunction. Spine. (Phila Pa 1976). 2013; 38(11): 909-915.

Rubinstein AL, Carpenter DM: Association between commonly prescribed opioids and androgen deficiency in men: A retrospective cohort analysis. Pain Med. 2016; 18(4): 637-644.

Amato L, Minozzi S, Davoli M, et al.: Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011; (9): CD005031.

Veterans Health Administration, Department of Veterans Affairs. VHA Pain Management for Providers. Available at https://www.va.gov/PAINMANAGEMENT/For_Providers.asp. Accessed May 16, 2017.

U.S. Department of Health and Human Services, National Institutes of Health, National Center for Complementary and Integrative Health. Chronic Pain: In Depth. Bethesda, Maryland: NCCIH, 2016; (NCCIH Publication No. D456) Available at https://nccih.nih.gov/health/pain/chronic.htm?nav=gsa. Accessed May 16, 2017.




DOI: http://dx.doi.org/10.5055/jom.2018.0436

Refbacks

  • There are currently no refbacks.
This site uses cookies to maintain session information critical to the user's experience and environment on this system. Click "Accept Cookies" to continue.
For more details please visit our privacy statement at: Privacy & GDPR